Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, BFA, PET, ANW

Modern Animal Unveils AI-Assisted Tools, Roadmap for Next Generation of Veterinary Care


CULVER CITY, Calif., May 22, 2024 /PRNewswire/ -- Modern Animal today unveiled an introductory suite of AI-assisted enhancements to its proprietary medical software, Claude. Designed to streamline administrative tasks that burden veterinary practitioners, these additions will elevate the quality of service for the nearly 60,000 pets and their families who trust the pioneering veterinary health network for care.

With more than 23 million families adopting pets in the first year of the pandemic, a surge in pet health concerns combined with staffing shortages has driven veterinarian burnout rates to an all-time high. Already integrated across Modern Animal's 20 clinic fleet in California and Texas, the first phase of features leverage Generative AI to begin addressing these issues by automating important, but tedious, administrative tasks that can consume nearly half of a doctor's time each day.

The three specific functions enhanced by AI in this first feature release are:

To ensure alignment between AI's capabilities, the needs of practitioners, and the integrity of Modern Animal's rigorous medical standards, these features were incubated in a unique collaboration between the Company's technology team and nearly 40 members of its clinical team. Clinicians who opted into this partnership beta-tested features, provided feedback, and were paired for "shadowing": an immersive practice whereby members of the technology team accompany practitioners throughout their day, ask questions, and identify opportunities for innovation in real-time.

According to Dr. Christie Long, Chief Medical Officer at Modern Animal and outspoken advocate for technology's application in veterinary medicine, the first set of features to emerge from this collaboration already have the potential to save doctors up to 2 hours per day. This time savings amounts to more manageable working hours, more collaborative and trusting relationships between veterinarians and pet owners, and begins to address catalysts for burnout that have become endemic within the veterinary profession.

"With AI streamlining tasks like records review, lab result interpretation and post-visit summary generation, our veterinarians can now dedicate more time to what truly matters: caring for pets and their families," says Dr. Long. "This newfound efficiency enables veterinarians to deliver care they feel proud of while also enhancing clinic productivity and, most importantly, their own quality of life."

With this initial rollout providing proof of AI's capacity to reduce administrative burdens, Modern Animal has its sights set on developing a more comprehensive suite of features that support doctors in practicing great medicine. On Modern Animal's blueprint for success in the next phase of development, the Company's Founder and CEO, Steven Eidelman, states, "The early investment we made to build our technology platform from scratch has uniquely positioned us to rapidly iterate and learn about AI's potential on our own terms. While so far we've used this advantage to augment our team's administrative efficiency, we have started to envision a world where AI becomes a reliable collaborator that increases confidence in medical decisions for doctors at all levels. I look forward to the continued impact of this important work on our network of practitioners and beyond."

To follow Modern Animal's progress, visit blog.modernanimal.com or follow the Company on LinkedIn, where they will publicly share case studies, product demos, and practical advice for other members of the veterinary community looking to augment their practice with AI.

Contact:
[email protected] 

SOURCE Modern Animal


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: